Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws
Key Highlights
- ➤DaVita stock fell $11.65, or approximately 6.23%, after HHS kidney-care strategy announcement
- ➤HHS plan targets dialysis-market concentration through competition measures and dominance penalties
- ➤Federal strategy shifts incentives toward early-stage preventive kidney care
- ➤Lowey Dannenberg investigates potential securities-law violations involving DaVita and its executives
Expert Statements
Andrea Farah, Partner and head of the securities practice at Lowey Dannenberg, P.C.
“Our investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,”
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating DaVita Inc. (NYSE: DVA) (“DaVita” or the “Company”) for potential violations of the federal securities laws.
On October 20, 2026, the U.S. Department of Health and Human Services (“HHS”) announced “a coordinated department-wide strategy focused on revitalizing American kidney care.” The federal plan targets the concentrated structure of the domestic dialysis market, in which DaVita is a dominant provider, by introducing new competition measures, penalizing entrenched market dominance, and shifting incentives toward early-stage preventive care. The investigation concerns whether DaVita and its officers and/or directors made false and/or misleading statements and/or failed to disclose the Company’s exposure to regulatory and competitive risks arising from its market position, and whether the Company had a reasonable basis for its positive statements about its business, financial condition, and prospects.
Get started
Create a free account to read the full story.